MicroRNAs and Cardiovascular Disease in Diabetes Mellitus

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Ding, Yue ^a   Sun, Xue ^a   Shan, Peng Fei ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; MICRORNA; PIOGLITAZONE; BIOLOGICAL MARKER; GLUCOSE; INSULIN;

ACUTE CORONARY SYNDROME; BASIC RESEARCH; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERPLASIA; LIPID METABOLISM; MACROPHAGE; NEOINTIMAL HYPERPLASIA; NONHUMAN; OUTCOME ASSESSMENT; REPOLARIZATION; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; VASCULAR SMOOTH MUSCLE CELL; ADIPOSE TISSUE; ANIMAL; ATHEROSCLEROSIS; BIOLOGICAL MODEL; CYTOLOGY; HOMEOSTASIS; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; PHENOTYPE; SKELETAL MUSCLE; VASCULAR SMOOTH MUSCLE;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLUCOSE; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MACROPHAGES; MICRORNAS; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; PHENOTYPE; PLATELET ACTIVATION;

EID: 85014227080     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/4080364     Document Type: Review

References (53)

1. D. Daneman, "Type 1 diabetes, " Lancet, vol. 367, no. 9513, pp. 847-858, 2006.
2. S. E. Daneman, "Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes, " The Journal of Clinical Endocrinology &Metabolism, vol. 86, no. 9, pp. 4047-4058, 2001.
3. E. P. Vamos, C. Millett, C. Parsons, P. Aylin, A. Majeed, and A. Bottle, "Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009, " Diabetes Care, vol. 35, no. 2, pp. 265-272, 2012.
4. G. A. Nichols, T. A. Hillier, J. R. Erbey, and J. B. Brown, "Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors, " Diabetes Care, vol. 24, no. 9, pp. 1614-1619, 2001.
5. D. Gradinaru, C. Borsa, C. Ionescu et al., "Nationwide study on trends in hospital admissions for major cardiovascular events and procedures among people with and without diabetes in England, 2004-2009, " Aging Clinical and Experimental Research, vol. 24, no. 6, pp. 595-602, 2012.
6. M. Ma and V. N. Kim, "Regulation of microRNA biogenesis, " Nature Reviews Molecular Cell Biology, vol. 15, no. 8, pp. 605-610, 2012.
7. X. Li, "miR-375, a microRNA related to diabetes, " Gene, vol. 533, no. 1, pp. 1-4, 2014.
8. S. Shantikumar, A. Caporali, and C. Emanueli, "Role of microRNAs in diabetes and its cardiovascular complications, " Cardiovascular Research, vol. 93, no. 4, pp. 583-593, 2012.
9. P. Kantharidis, B. Wang, R. M. Carew, andH. Y. Lan, "Diabetes complications: The microRNA perspective, " Diabetes, vol. 60, no. 7, pp. 1832-1837, 2011.
10. G. Arunachalam, A. P. Lakshmanan, S. M. Samuel, C. R. Triggle, andH. Ding, "Molecular interplay between microRNA-34a and sirtuin1 in hyperglycemia-mediated impaired angiogenesis in endothelial cells: effects of metformins, " Journal of Pharmacology and Experimental Therapeutics, vol. 356, no. 2, pp. 314-323, 2016.
11. A. Vikram, Y. Kim, S. Kumar et al., "Vascular microRNA-204 is remotely governed by the microbiome and impairs endothelium-dependent vasorelaxation by downregulating Sirtuin1, " Nature Communications, vol. 7, Article ID12565, 2016.
12. L. La Sala, M. Cattaneo, V. De Nigris et al., "Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells, " Cardiovascular Diabetology, vol. 15, article no. 71, 2016.
13. H.-W. Wang, S.-H. Su, Y.-L. Wang et al., "MicroRNA-134 contributes to glucose-induced endothelial cell dysfunction and this effect can be reversed by far-infrared irradiation, " PLoS ONE, vol. 11, no. 1, Article ID e0147067, 2016.
14. Q. Xu, S. Meng, B. Liu et al., "MicroRNA-130a regulates autophagy of endothelial progenitor cells through Runx3, " Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 5, pp. 351-357, 2014.
15. M. Ye, D. Li, J. Yang et al., "MicroRNA-130a targetsMAP3K12 to modulate diabetic endothelial progenitor cell function, " Cellular Physiology and Biochemistry, vol. 36, no. 2, pp. 712-726, 2015.
16. L. Maegdefessel, K. J. Rayner, and N. J. Leeper, "MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution, "Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 1, pp. 2-6, 2015.
17. M. A. Reddy, S. Das, C. Zhuo et al., "Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by MIR-504, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 5, pp. 864-873, 2016.
18. J. Yang, L. Chen, J. Ding et al., "MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1, " Gene, vol. 586, no. 2, pp. 268-273, 2016.
19. K. R. Cordes, N. T. Sheehy, M. P. White et al., "MiR-145 andmiR-143 regulate smooth muscle cell fate and plasticity, " Nature, vol. 460, no. 7256, pp. 705-710, 2009.
20. K. G. Chyu, W. P. Cheng, B. W. Wang et al., "Angiotensin II downregulates MicroRNA-145 to regulate kruppel-like factor 4 and myocardin expression in human coronary arterial smooth muscle cells under high glucose conditions, " Molecular Medicine, vol. 21, no. 1, pp. 616-625, 2015.
21. A. Elgheznawy, L. Shi, J. Hu et al., "Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes, " Circulation Research, vol. 117, no. 2, pp. 157-165, 2015.
22. G. Lugli, J. Larson, M. E. Martone, Y. Jones, and N. R. Smalheiser, "Dicer and eIF2c are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner, " Journal of Neurochemistry, vol. 94, no. 4, pp. 896-905, 2005.
23. C. D. Mills, "M1 and M2 macrophages: oracles of health and disease, " Critical Reviews in Immunology, vol. 32, no. 6, pp. 463-488, 2012.
24. J. L. Stoger, "Distribution of macrophage polarization markers in human atherosclerosis, " Atherosclerosis, vol. 225, no. 2, pp. 461-468, 2012.
25. X. Sun, J. Lin, Y. Zhang et al., "MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue, " Circulation Research, vol. 118, no. 5, pp. 810-821, 2016.
26. C. L. Kurtz, B. C. E. Peck, E. E. Fannin et al., "MicroRNA-29 finetunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes, " Diabetes, vol. 63, no. 9, pp. 3141-3148, 2014.
27. S. Wei, M. Zhang, Y. Yu et al., "HNF-4 regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in type 2 diabetic mice and in palmitatetreated HepG2 cells, " European Journal of Pharmacology, vol. 791, pp. 254-263, 2016.
28. Z.-Y. Li, Y. Xi, W.-N. Zhu et al., "Positive regulation of hepatic miR-122 expression by HNF4, " Journal of Hepatology, vol. 55, no. 3, pp. 602-611, 2011.
29. X. Fu, B. Dong, Y. Tian et al., "MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids, " Journal of Clinical Investigation, vol. 125, no. 6, pp. 2497-2509, 2015.
30. Y. Li, C.-M. Yang, Y. Xi et al., "MicroRNA-1/133 targeted dysfunction of potassium channels KCNE1 and KCNQ1 in human cardiac progenitor cells with simulated hyperglycemia, " International Journal of Cardiology, vol. 167, no. 3, pp. 1076-1078, 2013.
31. A. Zampetaki, S. Kiechl, I. Drozdov et al., "Plasma MicroRNA profiling reveals loss of endothelial MiR-126 and otherMicroRNAs in type 2 diabetes, " Circulation Research, vol. 107, no. 6, pp. 810-817, 2010.
32. Y. Mao, R. Mohan, S. Zhang, and X. Tang, "MicroRNAs as pharmacological targets in diabetes, " Pharmacological Research, vol. 75, pp. 37-47, 2013.
33. I. J. Gallagher, C. Scheele, P. Keller et al., "Integration of micro-RNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes, " GenomeMedicine, vol. 2, no. 2, article no. 9, 2010.
34. A. Caporali, M. Meloni, C. Völlenkle et al., "Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after Limb Ischemia, " Circulation, vol. 123, no. 3, pp. 282-291, 2011.
35. N. Klöting, S. Berthold, P. Kovacs et al., "MicroRNA expression in human omental and subcutaneous adipose tissue, " PLOS ONE, vol. 4, no. 3, Article ID e4699, 2009.
36. S. Wang, A. B. Aurora, B. A. Johnson et al., "The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and Angiogenesis, " Developmental Cell, vol. 15, no. 2, pp. 261-271, 2008.
37. C. Van Solingen, L. Seghers, R. Bijkerk et al., "Antagomirmediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis, " Journal of Cellular and Molecular Medicine, vol. 13, no. 8A, pp. 1577-1585, 2009.
38. A. Zernecke, K. Bidzhekov, H. Noels et al., "Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection, " Science Signaling, vol. 2, no. 100, p. ra81, 2009.
39. G. Al-Kafaji, G. Al-Mahroos, H. Abdulla Al-Muhtaresh, M. A. Sabry, R. Abdul Razzak, and A. H. Salem, "Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients, " Biomarkers, pp. 1-11, 2016.
40. R. Luthra, R. R. Singh, M. G. Luthra et al., "MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers, " Oncogene, vol. 27, no. 52, pp. 6667-6678, 2008.
41. H. Zhi, L. Wang, G. Ma et al., "Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease, " Clinical Research in Cardiology, vol. 101, no. 4, pp. 289-296, 2012.
42. J. Xu, Z. Z. Hu, Z. Xu et al., "Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population, " Human Mutation, vol. 30, no. 8, pp. 1231-1236, 2009.
43. B. Zhou, L. Rao, Y. Peng et al., "Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy, " Clinica Chimica Acta, vol. 411, no. 17-18, pp. 1287-1290, 2010.
44. Y.-M. Su, J. Li, Y.-F. Guo et al., "A functional single-nucleotide polymorphism in pre-microrna-196a2 is associated with atrial fibrillation in han chinese, " Clinical Laboratory, vol. 61, no. 9, pp. 1179-1185, 2015.
45. Q. Li, L. Chen, D. Chen, X. Wu, and M. Chen, "Influence of microRNA-related polymorphisms on clinical outcomes in coronary artery disease, " American Journal of Translational Research, vol. 7, no. 2, pp. 393-400, 2015.
46. J. B. Meigs, F. B. Hu, N. Rifai, and J. E. Manson, "Biomarkers of endothelial dysfunction and risk of Type 2 diabetes mellitus, " JAMA, vol. 291, no. 16, pp. 1978-1986, 2004.
47. M. Akcakoyun, R. Kargin, A. C. Tanalp et al., "Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: A Prospective Study, " Coronary Artery Disease, vol. 19, no. 5, pp. 337-343, 2008.
48. R. E. Gilbert, "Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications, " Circulation Journal, vol. 77, no. 4, pp. 849-856, 2013.
49. S. J. Hong, S. T. Kim, T. J. Kim et al., "Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation, " Journal of the American College of Cardiology, vol. 57, no. 14, pp. 2655-2665, 2011.
50. S. J. Hong, S. C. Choi, J. Y. Cho et al., "Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients-optical coherence tomography analysis, " Circulation Journal, vol. 79, no. 4, pp. 880-888, 2015.
51. P. Landry, I. Plante, D. L. Ouellet, M. P. Perron, G. Rousseau, and P. Provost, "Existence of a microRNA pathway in anucleate platelets, " Nature Structural and Molecular Biology, vol. 16, no. 9, pp. 961-966, 2009.
52. R. Shi, L. Ge, X. Zhou et al., "DecreasedplateletmiR-223 expression is associated with high on-clopidogrel platelet reactivity, " Thrombosis Research, vol. 131, no. 6, pp. 508-513, 2013.
53. Y.-Y. Zhang, X. Zhou, W.-J. Ji et al., "Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome, " Journal of Thrombosis and Thrombolysis, vol. 38, no. 1, pp. 65-72, 2014.